Drug Profile


Alternative Names: Alferon LDO; Alferon LDO (Low Dose Oral); Alferon N; Alferon N Gel; Alferon N Injection; Alferon N LDO; alpha-n3-IF; Altemol; Interferon alfa-N3; Interferon alfa-n3 human leukocyte derived (Alferon N Injection); Interferon-α-n3; Leukocyte interferon; Naturaferon; Natural alpha interferon

Latest Information Update: 09 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stem Cell Innovations
  • Developer Fujimoto Pharmaceutical; Hemispherx Biopharma; Howard University; National Institute of Allergy and Infectious Diseases; Swiss Department of Defence, Civil Protection and Sport; United States Army Medical Research Institute of Infectious Diseases
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Middle East respiratory syndrome coronavirus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Human papillomavirus infections
  • Registered Hepatitis C; Inflammation; Multiple sclerosis; Viral infections
  • Phase I Influenza virus infections
  • Preclinical Influenza A virus H7N9 subtype; Influenza A virus infections; Zika virus infection
  • Research Alphavirus infections; Ebola virus infections; Middle East respiratory syndrome coronavirus
  • No development reported HIV infections; West Nile virus infections
  • Discontinued Kaposi's sarcoma; Small cell lung cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Jun 2016 Hemispherx irrevocabaly obtains all intellectual property related to Alferon® under a comprehensive omnibus assignment
  • 31 May 2016 Hemispherx renews the sales, marketing, distribution and supply agreement with GP Pharm for interferon alpha n3 in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top